ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1512

Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Abstract Number: 1956

Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Abstract Number: 1076

Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Abstract Number: 0874

RNA-Binding Proteins That Are Highly Expressed and Enriched in Healthy Cartilage but Suppressed in Osteoarthritis
Abstract Number: 0729

ROCK1 Orchestrates B-cell Differentiation Under Stress
Abstract Number: 0862

Role of CRTAC1 as a Biomarker of Osteoarthritis
Abstract Number: 1114

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Abstract Number: 1778

Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Abstract Number: 0796

Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 0917

Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus
Abstract Number: 2353

Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Abstract Number: 2405

Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis
Abstract Number: 1771

Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Abstract Number: 0207

Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Abstract Number: 2506

Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].